含本托尼特肥在患有表皮溶解性 Ichthyosis 的患者的治疗效果
Kayla Zafar1,2, Austin Lee1, Margaret Kabakova1,3
1Dermatology Service, Veterans Affairs New York Harbor Healthcare System - Brooklyn Campus, Brooklyn, NY, US.
Archives of dermatological research
|March 26, 2025
概括
一种含有班托尼特的肥提供了一种新的,有效的治疗表皮溶解性 Ichthyosis (EI),一种遗传性皮肤疾病. 这种自然疗法显著改善了对传统治疗无反应的患者的皮肤缩和皮肤质感.
科学领域:
- 皮肤病学 皮肤病学
- 遗传学 是一个遗传学.
- 生物化学 生物化学
背景情况:
- 皮肤溶解性 Ichthyosis (EI) 是一种罕见的,自体主导的遗传性皮肤疾病.
- 在KRT1和KRT10基因的突变导致EI,导致皮肤变厚,状和容易出现水泡.
- 常规疗法,如氨酸乳酸和视网类药物,往往不能提供足够的症状管理.
研究的目的:
- 为了研究含有班托尼特的肥作为一种新型治疗药物的疗效,用于表皮溶解性 Ichthyosis.
- 评估本托尼特肥对患有EI的患者皮肤脱落和纹理的影响.
主要方法:
- 一份病例报告详细介绍了诊断为EI的70岁女性患者的治疗方法.
- 在患者的现有治疗方案中加入含本托尼特的肥,其中包括氨酸乳酸和剥皮浴.
- 评估患者报告的皮肤缩,纹理和整体改善的结果.
主要成果:
- 患者在加入本托尼特肥后,皮肤脱落显著改善,特别是在手和脚上.
- 观察到皮肤厚度的减少和皮肤光滑度的增加,表明皮肤屏障功能增强.
- 班托尼特肥表现出皮,抗菌和伤口愈合特性,有利于EI管理.
结论:
- 含有本托尼特的肥显示出作为一种有效和新的治疗方案来管理表皮溶解性 Ichthyosis 的潜力.
- 班托尼特的天然特性,包括其恢复皮肤屏障的能力,可能有助于其治疗效益.
- 需要进一步进行临床试验,以证实本顿基产品在EI治疗中的长期安全性和有效性.
相关概念视频
01:19Clinical Applications of Epidermal Stem Cells
2.7K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.7K
01:23Hand hygiene
3.1K
Asepsis is the practice of preventing or breaking the chain of infection. The nurse employs aseptic techniques to prevent the spread of microorganisms and reduce the risk of diseases. Hand hygiene is the cornerstone of aseptic techniques and is classified into medical and surgical asepsis. Medical asepsis includes hand hygiene and the use of gloves. Surgical asepsis, or the sterile technique, refers to practices that render and keep objects and areas free of microorganisms.
Hand washing...
Hand washing...
3.1K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
114
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
114
01:29Inflammatory Bowel Disease IV: Pharmacological Management
83
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
83
01:21Drugs for Treatment of Constipation-Predominant IBS
124
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
124